Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 974-979

  Kaneko, Akira ^a   Bergqvist, Yngve ^b   Takechi, Miho ^b   Kalkoa, Morris ^b   Kaneko, Osamu ^b   Kobayakawa, Takatoshi ^b   Ishizaki, Takashi ^b   Björkman, Anders ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CHLOROQUINE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; PROGUANIL; PYRIMETHAMINE; SULFADOXINE;

ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; MIXED FUNCTION OXYGENASES; TETRAHYDROFOLATE DEHYDROGENASE; TRIAZINES;

EID: 0032926172     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314683     Document Type: Article

References (33)

1. Curd FHS, Davey DG, Rose FL. Studies on synthetic antimalarial drugs. X: Some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann Trop Med Parasitol 1945; 39:208-16.
2. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL. A metabolite of "Paludrine" with high antimalarial activity. Nature 1951; 168:1080.
3. Watkins WM, Sixsmith DG. The activity of proguanil and its metabolites,cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann Trop Med Parasitol 1984; 78:273-8.
4. Eriksson B, Lebbad M, Björkman A. In vitro activity of proguanil, chlorproguanil, and their main metabolites against Plasmodium falciparum.Trans R Soc Trop Med Hyg 1989; 83:488.
5. Bzik DJ, Li WB, Horii T, Inserburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase thymidylate synthase gene. Proc Natl Acad Sci USA 1987; 84:8360-4.
6. Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 1990; 87:3014-7.
7. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990; 87:3018-22.
8. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347: 1511-4.
9. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomized placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-13.
10. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism a panel study. Br J Clin Pharmacol 1991; 31:689-92.
11. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29:192-209.
12. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S- mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6:521-6.
13. Masimirembwa C, Bertilsson L, Johansson I. Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57:656-61.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-8.
15. Kaneko A, Kaneko O, Taleo G, Björkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997; 349:921-2.
16. Kaneko A, Taleo G, Kalkoa M, et al. Malaria epidemiology, glucose 6- phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. Acta Trop 1998; 70:285-302.
17. Uchida JY, Kasahara T, Bobogare A, et al. The prevalence of falciparum malaria in the Solomon Islands investigated by a filter paper disk PCR method. Jpn J Parasitol 1995; 44:119-27.
18. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 1996; 55:209-13.
19. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 1997; 94:1124-9.
20. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62-6.
21. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 1996; 313:525-8.
22. Nguyen-Dinh P, Spencer HC, Chemangey-Masaba S, Churchill FC. Susceptibility of Plasmodium falciparum to pyrimethamine and sulfadoxine/pyrimethamine in Kisumu, Kenya. Lancet 1982; 1:823-5.
23. Masaba SC, Anyona DB, Chepkwoni DK. In vitro response of Plasmodium falciparum to chloroquine in the Nandi district, Kenya. Bull World Health Organ 1985; 63:593-5.
24. Edstein MD, Looareesuwan S, Wilairatana P, Vanijanonta S, Kyle DE, Rieckmann KH. Disposition of proguanil in Thai patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 1997; 56:498-502.
25. Edstein MD, Yeo AET, Kyle DE, Looareesuwan S, Wilairatana P, Rieckmann KH. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. Trans R Soc Trop Med Hyg 1996; 90:418-21.
26. Björkman A. Drug resistance-changing patterns. In: Target G, ed. Malaria, waiting for the vaccine. Chichester, UK: John Wiley & Sons, 1991:105-20.
27. Mberu EK, Wansor T, Sato H, Nishikawa Y, Watkins WM. Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Trans R Soc Trop Med Hyg 1995; 89:658-9.
28. Fidock DA, Wellems TE. Transformation with human dihydrofolate reduc tase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci USA 1997; 94: 10931-6.
29. Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 1979; 73:15-7.
30. Seaton DR, Lourie EM. Acquired resistance to proguanil (Paludrine) in Plasmodium vivax. Lancet 1949; 1:394-5.
31. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183-4.
32. Eldin de Pécoulas P, Basco LK, Tahar R, Ouatas T, Mazabraud A. Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene 1998; 211:177-85.
33. Tahar R, de Pécoulas PE, Mazabraud A, Basco LK. Plasmodium vivax: rapid detection by polymerase chain reaction and restriction fragment length polymorphism of the key mutation in dihydrofolate reductase-thymidylate synthase gene associated with pyrimethamine resistance. Exp Parasitol 1998; 89:343-6.